Additionally, USP13 is reported to improve the DNA damage response by recruiting the RAP80-BRCA complex to DNA damage sites in ovarian cancer, indicating that USP13 is a potential target to enhance the effectiveness of DDR inhibitors in cancers [25]. Here, USP13 is linked to ovarian carcinoma.